AHK-Cu

AHK-Cu, or Alanyl-Histidyl-Lysine copper tripeptide, is a copper-binding peptide related to the more widely studied GHK-Cu, distinguished by its amino acid sequence and research focus that includes hair follicle biology alongside general skin support. It has drawn research interest for its proposed effects on vascular endothelial growth factor (VEGF) expression and dermal papilla cell activity, both implicated in hair growth cycles. This profile addresses AHK-Cu in the context of reconstituted, subcutaneous protocols, which is less studied overall than topical application. Human clinical data specific to this exact peptide remains limited compared to its better-known counterpart GHK-Cu. Reported benefits include studied for potential effects on vegf expression relevant to hair follicle blood supply, investigated for possible influence on dermal papilla cell activity linked to hair growth cycles, explored alongside other copper peptides for general tissue-support properties.

Reported ranges run 1-3 mg. A low protocol is 1 mg once daily or every other day, and a high protocol is 3 mg once daily, at the higher end of ranges discussed in research and community protocols. This is reference information, not a dosing recommendation.

Short, generally cited in the range of minutes to a few hours for similar copper-peptide complexes, though tissue effects may persist beyond plasma clearance.. That is what sets the dosing frequency, and it is why the timing guidance is evening.

Subcutaneous: into fat, under the skin. This profile covers AHK-Cu in reconstituted, injectable/subcutaneous protocols rather than conventional topical cosmetic formulations.

Multi-week cycles of daily or near-daily dosing are commonly described on, followed by Periodic breaks are often suggested to avoid cumulative copper exposure off. Monitoring of copper levels may be advisable with extended or repeated cycles given copper's potential for tissue accumulation.

Reported side effects include injection site irritation or redness, potential for copper accumulation with excessive or prolonged use, limited long-term human safety data for injectable administration, possible sensitivity reactions in susceptible individuals. Evidence level for this compound is emerging research.